Seres Therapeutics Stock Buy Hold or Sell Recommendation
| MCRB Stock | USD 0.92 0.04 4.55% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Seres Therapeutics is 'Strong Sell'. Macroaxis provides Seres Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding MCRB positions.
Check out Seres Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide. In addition, we conduct extensive research on individual companies such as Seres and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Seres |
Execute Seres Therapeutics Buy or Sell Advice
The Seres recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Seres Therapeutics. Macroaxis does not own or have any residual interests in Seres Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Seres Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Seres Therapeutics Trading Alerts and Improvement Suggestions
| Seres Therapeutics had very high historical volatility over the last 90 days | |
| Seres Therapeutics has some characteristics of a very speculative penny stock | |
| Seres Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 126.33 M. Net Loss for the year was (113.72 M) with loss before overhead, payroll, taxes, and interest of (165.79 M). | |
| Seres Therapeutics currently holds about 195.8 M in cash with (117.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Seres Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 13.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Seres Therapeutics to Participate in Piper Sandler Healthcare Conference |
Seres Therapeutics Returns Distribution Density
The distribution of Seres Therapeutics' historical returns is an attempt to chart the uncertainty of Seres Therapeutics' future price movements. The chart of the probability distribution of Seres Therapeutics daily returns describes the distribution of returns around its average expected value. We use Seres Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Seres Therapeutics returns is essential to provide solid investment advice for Seres Therapeutics.
| Mean Return | 0.37 | Value At Risk | -9.78 | Potential Upside | 10.84 | Standard Deviation | 6.57 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Seres Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Seres Stock Institutional Investors
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 342.2 K | Lion Point Capital, Lp | 2024-09-30 | 340.8 K | State Street Corp | 2024-06-30 | 339.5 K | Verition Fund Managegment, Llc | 2024-06-30 | 314.2 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 267.4 K | Bridgeway Capital Management, Llc | 2024-09-30 | 250 K | Citigroup Inc | 2024-09-30 | 218.2 K | Northern Trust Corp | 2024-09-30 | 218.2 K | Ubs Group Ag | 2024-06-30 | 200.7 K | Flagship Ventures Management, Inc. | 2024-06-30 | 23.1 M | Fmr Inc | 2024-09-30 | 22.9 M |
Seres Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (20.8M) | 50.9M | 72.0M | (16.8M) | (35.1M) | (33.3M) | |
| Free Cash Flow | (77.5M) | (94.2M) | (2.9M) | (238.6M) | (125.3M) | (119.1M) | |
| Depreciation | 7.6M | 6.6M | 5.9M | 6.6M | 6.2M | 4.9M | |
| Other Non Cash Items | 2.3M | 3.3M | 2.0M | 7.6M | 15.0M | 15.8M | |
| Capital Expenditures | 1.0M | 591K | 9.6M | 9.8M | 8.0M | 5.8M | |
| Net Income | (70.3M) | (89.1M) | (65.6M) | (250.2M) | (113.7M) | (119.4M) | |
| End Period Cash Flow | 65.1M | 116.0M | 188.0M | 171.2M | 136.2M | 96.2M | |
| Investments | (29.5M) | (158.3M) | 73.7M | 92.2M | 17.4M | 18.3M | |
| Change To Netincome | 8.7M | 8.8M | 24.3M | 25.5M | 29.3M | 16.2M |
Seres Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Seres Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Seres Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Seres stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.32 | |
β | Beta against Dow Jones | 0.32 | |
σ | Overall volatility | 6.66 | |
Ir | Information ratio | 0.04 |
Seres Therapeutics Volatility Alert
Seres Therapeutics is displaying above-average volatility over the selected time horizon. Seres Therapeutics is a potential penny stock. Although Seres Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Seres Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Seres instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Seres Therapeutics Fundamentals Vs Peers
Comparing Seres Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Seres Therapeutics' direct or indirect competition across all of the common fundamentals between Seres Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Seres Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Seres Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Seres Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Seres Therapeutics to competition |
Note: Disposition of 927 shares by Matthew Henn of Seres Therapeutics at 0.5407 subject to Rule 16b-3 [view details]
Seres Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Seres . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Seres Therapeutics Buy or Sell Advice
When is the right time to buy or sell Seres Therapeutics? Buying financial instruments such as Seres Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Seres Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Treasury ETFs Thematic Idea Now
Treasury ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Treasury ETFs theme has 114 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Treasury ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Seres Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.40) | Revenue Per Share 0.871 | Quarterly Revenue Growth (0.93) | Return On Assets (0.1) | Return On Equity (15.56) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.